Rosiglitazone Alleviates the Persistent Fibrotic Phenotype of Lesional Skin Scleroderma Fibroblasts

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2009 Dec 17

PMID 20007285

Citations 32

Authors

Xu Shi-Wen

Mark Eastwood

Richard J Stratton

Christopher P Denton

Andrew Leask

David J Abraham

Affiliations

Soon will be listed here.

Abstract

Objective: The transcription factor peroxisome proliferator-activated receptor (PPAR)-gamma plays an important role in controlling cell differentiation. The aim of the present study was to examine whether PPAR-gamma expression was reduced in skin scleroderma fibroblasts and whether PPAR-gamma agonists could suppress the persistent fibrotic phenotype of skin scleroderma fibroblasts.

Methods: Dermal fibroblasts were isolated from site-, age- and sex-matched healthy individuals and lesional areas of individuals with dcSSc. Western blot and collagen gel contraction analyses were used to detect protein expression in the presence or absence of the PPAR-gamma agonist rosiglitazone.

Results: PPAR-gamma expression was reduced in dcSSc fibroblasts. The PPAR-gamma agonist rosiglitazone alleviated the persistent fibrotic phenotype of dcSSc fibroblasts.

Conclusion: Rosiglitazone may alleviate the extent of fibrosis in dcSSc.

Citing Articles

The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases.

Posta E, Fekete I, Varkonyi I, Zold E, Barta Z Cells. 2024; 13(20.

PMID: 39451206 PMC: 11505700. DOI: 10.3390/cells13201688.

Multiple gene-drug prediction tool reveals Rosiglitazone based treatment pathway for non-segmental vitiligo.

Zhao S, Chen X, Dutta K, Chen J, Wang J, Zhang Q Inflammation. 2023; 47(2):678-695.

PMID: 38159176 PMC: 11074021. DOI: 10.1007/s10753-023-01937-9.

Fibroblasts are not just fibroblasts: clear differences between dermal and pulmonary fibroblasts' response to fibrotic growth factors.

Madsen S, Sand J, Juhl P, Karsdal M, Thudium C, Siebuhr A Sci Rep. 2023; 13(1):9411.

PMID: 37296166 PMC: 10256773. DOI: 10.1038/s41598-023-36416-6.

Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease.

Cerro-Chiang G, Ayres M, Rivas A, Romero T, Parker S, Mastali M Sci Rep. 2023; 13(1):8645.

PMID: 37244972 PMC: 10224939. DOI: 10.1038/s41598-023-35840-y.

Lobeglitazone attenuates fibrosis in corneal fibroblasts by interrupting TGF-beta-mediated Smad signaling.

Nuwormegbe S, Park N, Kim S Graefes Arch Clin Exp Ophthalmol. 2021; 260(1):149-162.

PMID: 34468828 DOI: 10.1007/s00417-021-05370-2.